It is well known that after acute exacerbations of multiple sclerosis (MS) some of the acute manifestations may improve spontaneously. For (Brandriss et al., 1965) . Unfortunately, the comparable use of these drugs in MS is limited by the inability to anticipate the appearance of a new exacerbation in order to administer preventative treatment. However, one drug-cyclophosphamide-has been shown by several workers (Field, 1969; Paterson and Drobish, 1969; Paterson, 1971) to reverse the course of EAE even when administered after signs of nervous system dysfunction have appeared. In these studies cyclophosphamide produced prompt and striking reversal of EAE in a large majority of animals, even if treatment was delayed for as long as five days after the appearance of paralysis, and continued treatment successfully prevented the reappearance of clinical EAE. More dramatically, histological examination of the brain and spinal cord showed that cyclophosphamide reduced the histopathological changes in treated animals compared with controls (Paterson, 1971 (Paterson and Drobish, 1969; Paterson, 1971) ; and on evidence that cyclophosphamide produces immunosuppression in humans within this period (Santos et al., 1970) . STATISTICAL METHODS Since this was designed as a pilot study, arbitrary decisions were made for an 'acceptable' success rate and a 'reasonable' sample size. It was decided arbitrarily that if significantly more than 5000 of patients showed arrest of exacerbations of MS this would be sufficient preliminary evidence on which to plan a more definitive study. The maximum sample size was set at 20 patients, based on estimates of the rate at which patients within the available clinical population presented with new exacerbations; and the justification for a trial of a drug of known toxicity and unknown efficacy in volunteer MS patients.
A sequential criterion method was used to inspect the data periodically (Armitage, 1960 (Armitage, , 1971 . This method utilizes a 'stopping rule', which enables the investigator to determine the earliest point at which the data reach statistical significance, or the first point at which, within a maximum sample size (20 In the four patients in whom the phase 1 deficits progressed, increasing symptoms and signs were noted throughout the course of the hospital portion of the study-that is, for 21 days. In two patients, phase 1 deficits were arrested by the third and fourth days respectively. In five patients, phase 2 deficits appeared after the fifth day of treatment, beginning on the fifth day in three and the seventh day in two patients, and continuing for between five and nine days subsequently.
Since all of the first six patients were treatment failures by the predetermined criteria, the study was discontinued according to the sequential stopping rule; the possibility of statisticallysignificant success within sample size of 20 patients had been eliminated. (Field, 1969; Paterson and Drobish, 1969; Paterson, 1971) . However, we could find no pattern of change in neurological signs and symptoms to suggest that cyclophosphamide altered the clinical course of the patients, and it appeared that the acute manifestations of MS progressed in a typical fashion. The results of the pilot study contrasted sharply with the results obtained by the use of cyclophosphamide in EAE.
The possible relation of EAE to MS has been strongly suggested for many years, largely based on the similarity of the pathological lesion in the two conditions (Wolf, 1963; Levine, 1971) . The relationship has been emphasized by studies of Bornstein and coworkers demonstrating the presence of presumptive antibodies both in animals with EAE and in patients with MS that, with the aid of complement, prevent myelination in neuronal tissue culture, and interfere with synaptic transmission (Bornstein and Appel, 1961, 1965; Bornstein, 1972) . Other findings, including the presence of IgG in the lesion of MS (Tourtellotte and Parker, 1967) give further support to this immunological relationship. Reservations about the similarities of the two conditions arise from the inability of many investigators to demonstrate cutaneous hypersensitivity, circulating antibodies of conventional types, or in vitro cellular responses to presumptive antigenic substances (Mackay et al., 1973; Paterson, 1973) .
Presumptions that MS has an immunological basis have led to trials of several immunosuppressive agents using a variety of regimens, with generally unsuccessful results. In most of these studies the immunosuppressive agents were given chronically in an effort to prevent progression or exacerbations of MS (Millac and Miller, 1969; MacFadyen et al., 1973; Silberberg et al., 1973) . Silberberg et al. (1973) found no benefit in the chronic use of azathioprine in 15 patients with MS; nor did Millac and Miller (1969) find that long-term cyclophosphamide treatment altered the course of MS in nine patients maintained for a year on this drug. MacFadyen et al. (1973) noted no improvement or alteration in course in four patients treated with antilymphocyte globulin (ALG) for brief periods. Only in the large scale studies of ACTH has any anti-inflammatory or immunosuppressive regimen shown a consistent pattern of benefit, and that was noted to be a temporary one (Rose et al., 1970) .
The present trial of cyclophosphamide in MS differs from previous studies in several particulars. Only patients with acute exacerbations of very recent onset, or those with recently progressing signs, were included in the study. The use of this highly selected patient group provided the opportunity to observe whether rapid institution of effective immunosuppression could halt the progress of disease or prevent the development of new manifestations during a period of MS 'activity', in a manner closely comparable with the effective use of cyclophosphamide in EAE. Failure to reproduce the results seen in EAE in these ideal circumstances further weakens the possibility that other-either acute or chronicimmunosuppressive regimens would realistically hold out hope for benefit.
Several explanations should be considered for the failure of this acute immunosuppressive regimen to halt the progress of exacerbations of MS despite its effectiveness in reversing EAE:
1. Cyclophosphamide may fail to penetrate the blood-brain barrier in MS patients, even at the site of recent involvement and, presumably, histopathological change.
2. Since an exacerbation of MS represents a recurrence of disease, 'memory' immunocytes would be involved in any immunological response, in contrast with the primary-type response to nervous tissue antigen in EAE. Cyclophosphamide is well known to be more effective in suppressing primary than secondary immune responses (Gabrielsen and Good, 1967) ; this immunological difference might explain the effectiveness of treatment in EAE and its failure in MS. Illustrating this point, one patient (after cyclophosphamide treatment) showed loss of in vitro lymphocyte transformation to the nonspecific mitogen, PHA; while lymphocyte transformation to a previously-experienced antigen -monilia-persisted despite treatment.
3. Alternatively, a purely immunological model may be an incorrect explanation for clinical MS. The human disease may be the result of several interactive mechanisms-such as persistent virus infection with a host immune response (Johnson and Weiner, 1972; Adams and Dickinson, 1974 )-or it may result from a primarily non-immunological process.
The use of a pilot study with the sequential analysis method of determining a 'stopping rule' seems a particularly appropriate method for evaluating drug treatment in this disease. From a practical standpoint, we were not interested in determining whether cyclophosphamide treatment provided a minimal percentage benefit over non-treatment; only a major alteration of the course of the disease in a majority of patients would justify further investigation or treatment with this agent. Sequential analysis permitted us to draw a practical, negative conclusion with a relatively small group of patients. It may be recommended as an economical method of conducting other pilot studies, with sample size and criteria for success set appropriately for the experimental design.
This study, like all clinical investigations of the response of MS patients to a treatment regimen, is hampered by the absence of a reliable indicator of disease activity, and the need to rely 
